Skip to content
Blocking two molecular pathways simultaneously gives better anti-tumour activity

Blocking two molecular pathways simultaneously gives better anti-tumour activity

Get the podcast

ORLANDO—Evidence that cancer could be controlled more effectively by blocking two molecular pathways simultaneously was reported at the American Association for Cancer Research annual meeting in Orlan

The Audio Journal of Oncology
Johanna Bendell

Johanna Bendell

ORLANDO—Evidence that cancer could be controlled more effectively by blocking two molecular pathways simultaneously was reported at the American Association for Cancer Research annual meeting in Orlando, Florida.Johanna Bendellfrom the Sarah Cannon Research Institute in Nashville, Tennessee discusses her group’s findings in research using inhibitors of both the P13K-AKT-mTOR and RAS-RAF-MEK pathways in a group of patients with a range of different advanced solid tumours.

LISTEN

More from AACR 2011

All 2 interviews

This is the last of the 2 AACR 2011 interviews. See them all.

Related Episodes

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?

Mitchell E Fane PhD; AACR 2026: Gamma Delta T-Cell Modulation: a Potential New Component of Immunotherapy for Patients with Metastatic Cutaneous Melanoma?

SAN DIEGO, USA—The importance of gamma delta T-cells in the progression of cutaneous metastatic melanoma was highlighted at the 2026 Annual Meeting of the American Association for Cancer Research. Epidemiological evidence of a relationship between these very specialized cells and the age-dependency of cancer progression has now been linked to powerful laboratory-based in-vivo studies suggesting a potential role of gamma delta T-cells as components of cancer immunotherapy. Peter Goodwin talked with first author of the research, Mitchell E Fane, Assistant Professor at the Fox Chase Cancer Center’s Cancer Signaling and Microenvironment Program in Philadelphia, USA:

10 Nov 2026
10 min
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”

Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome” An interview with: Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma Univer

4 Jun 2026
11 min
Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma

Omar Nadeem MD 2026 AACR: BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma

BCMA-directed CAR T-cell Therapy Highly Effective In Patients with High-Risk Smoldering Multiple Myeloma An interview with: Omar Nadeem MD, Medical Oncologist and Clinical Investigator, Dana-Farber Ca

21 May 2026
11 min